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Abstract: Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract 
  characterized by recurring flares followed by periods of inactive disease and remission. The 
etiology is unknown, although the common opinion is that the disease arises from a disordered 
immune response to the gut contents in genetically predisposed individuals. Infliximab (IFX), 
a chimeric immunoglobulin G1 monoclonal antibody to tumor necrosis factor, has dramatically 
changed the approach to managing patients with CD and improving their treatment, by achiev-
ing treatment goals, such as mucosal healing, and decreasing the need for hospitalizations and 
surgeries. This review provides an update on existing evidence for the use of IFX in CD, taking 
into account the safety profile in clinical practice and special situations such as pregnancy. 
Antitumor necrosis factor therapy has been evaluated as an induction and maintenance therapy 
in CD in several randomized controlled trials and meta-analyses, showing efficacy in both 
clinical settings. Early use of biologics may improve patient outcomes in active CD. However, 
a widespread use of a “  top-down” approach in all CD patients cannot be recommended. Clinical 
factors at diagnosis may predict poor outcome in CD, and should be taken into account when 
determining the initial therapeutic approach.
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Introduction
Current models of Crohn’s disease (CD) indicate an initial disturbance of the epithelial 
interface between the gut mucosa and intestinal microbiota, suggesting that mucosal 
damage by luminal bacteria is an early, initiating factor in the etiopathogenesis of 
the disease. However, a number of features of CD argue against a primary mucosal 
process, including phenotypic studies of patients with CD that point to a macrophage 
defect and genetic studies that predict impaired innate immunity to intracellular 
bacteria. A contemporary working model suggests an immunologic defect plus the 
presence of certain bacteria, stimulating a variety of experimental models that aim 
to dissect the mucosal immune response to intestinal microbiota as a function of 
defined chemical, genetic, or immunologic perturbations. The intestinal flora as a 
whole and specific bacteria and their products have been found to trigger cytokine 
expression in various cell types. Consistently, multiple bacterial strains were found 
to induce tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-8 in macrophage 
and epithelial cell systems, respectively, in particular in CD. In inflammatory bowel 
disease (IBD), the evidence indicates that dysregulation of mucosal immunity in the 
gut causes an overproduction of inflammatory cytokines and trafficking of effector 
leukocytes into the bowel, leading to uncontrolled   intestinal inflammation. Under Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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normal conditions, the intestinal mucosa is in a state of 
“controlled” inflammation regulated by a delicate balance 
of proinflammatory (TNF, interferon-gamma [IFN-γ], IL-1, 
IL-6, IL-12), and anti-inflammatory (IL-4, IL-10, IL-11) 
cytokines.
interleukin-1 and tumor necrosis  
factor-alpha
IL-1 and TNF-α share a multitude of proinflammatory 
properties and appear to be critical to the amplification of 
mucosal inflammation in IBD. Both cytokines are primarily 
secreted by monocytes and macrophages upon activation, 
and induce intestinal macrophages, neutrophils, fibroblasts, 
and smooth muscle cells to produce prostaglandins, pro-
teases, and other soluble mediators of inflammation and 
injury, as well as other inflammatory and chemotactic 
cytokines. An enhanced expression of IL-1 and TNF-α was 
found in inflammatory bowel disease, and the important 
role of TNF-α was also confirmed in the genesis of these 
diseases. TNF-α has several biologic activities that may 
be directly related to the pathogenesis of IBD, and there 
is increasing evidence suggesting a central role for TNF-α 
in CD.1 The effects of TNF-α in the intestine are disrup-
tion of the epithelial barrier, induction of apoptosis of the 
villous epithelial cells and secretion of chemokines from 
the intestinal epithelial cells. TNF-α activates endothelium 
by upregulating E-selectin and other adhesion molecules, 
such as intercellular adhesion molecule-1, as well as by 
inducing the expression of cytokines and   chemokines. 
Several studies have shown that TNF-α production is 
increased in the intestinal mucosa2 and in the serum of 
patients with CD.3
Prior to the introduction of biologic agents in the late 
1990s, patients with moderate-to-severe CD or fistulous 
CD had few nonsurgical options. Systemic corticosteroid 
therapy is effective for acute CD, and budesonide may be 
an alternative for those with terminal ileal CD for whom 
systemic steroid adverse effects are a concern. These 
drugs are not recommended for maintenance therapy in 
IBD. Immunosuppressants are generally not recommended 
for inducing remission in active CD. The exception to 
this is that intramuscular methotrexate may be of benefit 
as an adjunct to steroids in inducing remission in CD. 
The thiopurine immunosuppressive agents, azathioprine, 
6-mercaptopurine, and methotrexate, are   effective steroid-
sparing drugs that maintain remission in patients with CD. 
Infliximab (IFX) is a chimeric mouse/human monoclonal 
IgG1 antibody comprised of 75% human and 25% murine 
sequences, which has a high   specificity for and affinity 
to TNF-α, and neutralizes the biologic activity of TNF-α 
by inhibiting binding to its receptors. It has proven to 
be a powerful new tool for the treatment of moderately 
to severely active CD that is refractory to conventional 
therapy.
In parallel with IFX, two more humanized anti-TNF-α 
agents were developed. Adalimumab is a fully human 
recombinant IgG1 monoclonal antibody against TNF-α, 
and is approved for use in rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, and luminal CD. Unlike 
IFX, adalimumab is administered by subcutaneous injec-
tion and can be easily self-administered every 2 weeks. 
Certolizumab pegol (CDP-870) is a pegylated humanized 
fragment antigen binding (Fab) that binds TNF-α; it is 
administered subcutaneously and has been approved in the 
US for treatment of CD.4,5 The choice of first anti-TNF-α 
agent will depend greatly on the personal preference of 
the treating physician and the patient’s perspectives on 
convenience issues. The objective of this paper was to 
review the role of IFX in patients with CD, in terms of 
clinical efficacy and safety in various indications. Table 1 
lists current indications and contraindications for IFX 
therapy in CD.
Induction of remission in patients  
with active CD
Multiple studies have evaluated the efficacy of IFX in 
patients with active luminal CD. Several centers have also 
published their clinical experience with IFX, which provides 
further insight into the effectiveness of IFX outside of the 
clinical trials setting. Approval was based upon the results 
of two randomized controlled trials (a single-dose trial 
and a multiple-dose trial) involving a total of 653 patients 
with moderately to severely active CD (Crohn’s Disease 
Table 1 Indications and contraindications for infliximab therapy 
in CD
Indications Contraindications
Refractory luminal CD Active abscess or infections
Steroid-dependent CD Suspected active tuberculosis
Refractory fistulizing CD intestinal obstruction
Systemic manifestations  
of iBD
Multiple sclerosis or optical neuritis
Pyoderma gangrenosum Previous lymphoma or neoplastic disease
Chronic uveitis Heart failure
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Activity Index [CDAI] $220 and #400) who had responded 
inadequately to conventional therapy.6,7 The results are con-
firmed by a Cochrane review8 and by two meta-analyses9,10 
of placebo-controlled trials that evaluated the efficacy of 
TNF-α antagonists for luminal disease demonstrating that 
IFX is more efficacious than placebo in inducing remission 
in moderate to severely active luminal CD.
The efficacy of IFX for induction of clinical remission 
is summarized in Figure 1 which shows an overall analysis 
of trials for induction of remission at week 4, with a number 
needed to treat of three, based on only one small study per-
formed by Targan et al.6 This single-dose trial included 108 
patients with moderate-to-severe CD who were randomly 
assigned to a single 2-hour intravenous infusion of either 
placebo or IFX by comparing doses of 5, 10, and 20 mg/
kg with placebo. At 4 weeks of follow-up, 22 of 27 patients 
(81%) who received IFX at a dose of 5 mg/kg, 14 of 28 
(50%) who received 10 mg/kg, and 18 of 28 (64%) who 
received 20 mg/kg had a clinical response compared with 
four of 24 (17%) who received placebo. Remission occurred 
significantly more often in those randomized to IFX (33% 
of the treated group overall vs 4% of the placebo group). 
The clinical response persisted in many patients over the 
12 weeks of follow-up (41% vs 12%). Statistical analyses 
demonstrated no effect of concomitant medication or dis-
ease location on response rates or remission rates. There 
was no statistically significant difference between the three 
doses of IFX used in the trial, although the 5 mg/kg body 
weight dose consistently yielded the highest response and 
remission rates.
Experience with IFX has accumulated rapidly since 
the initial controlled trial demonstrating the role of IFX in 
inducing clinical remission in active luminal CD   disease. 
A report from the University of Chicago that included 129 
treated patients with intestinal disease found the median time 
to initial response was 8 days, with a 65% response rate at 
3 weeks. The median time to remission was 9 days, with a 
31% response rate.11 Relapse occurred in 78% of patients at 
a mean of 8.5 weeks. Steroid tapering was seen in more than 
90% of patients, with 54% able to stop steroids. Treatment 
of patients with IFX markedly decreases endoscopic and 
histologic disease activity in Crohn’s colitis.12,13 An Italian 
multicenter study involving 12 centers and 573 patients by 
Orlando et al14 represents a large and valuable Italian experi-
ence addressing the question of predictive factors determin-
ing the response to IFX in CD. The primary endpoints of the 
study were clinical response and clinical remission in patients 
with luminal refractory disease treated with a dose of 5 mg/
kg. Patients were followed for at least 6 months after infusion, 
showing that 322 patients (84.1%) had a clinical response 
12 weeks after the first infusion and 228 (59.5%) reached 
clinical remission. This study identifies the use of a single 
infusion and previous resectional surgery as negative predic-
tive factors of IFX response in refractory luminal disease. 
Hanauer 2006 (Classic-I) ADA
Sandborn 2007 (Gain) ADA
Sandborn 2001 CDP571
Sandborn 2004 CDP571
Sandborn 2007 (Precise 1) CERTO
Schreiber 2005 CERTO
Winter 2004 CERTO
Sandborn 2001 ETANERCEPT
Targan 1997 IFX
Total (Heterogeneity, P = 0.22)
12
Weight (%)
14
12
14
17
13
5
4
9
14% (4–23%)
14% (7–22%)
5% (−5–14%)
5% (−3–13%)
8% (3–13%)
13% (5–21%)
18% (−1–38%)
11% (−32–10%)
29% (16–41%)
11% (6–16%
          P < 0.001)
100
Risk difference
Difference in effect:  treatment minus placebo (CI: 95%)
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Figure 1 Overall analysis of trials evaluating the effect of antitumor necrosis factor (including adalimumab and certolizumab) for induction of remission at week 4.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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In summary, evidence from the controlled trials and 
  meta-analyses supports the use of   biological therapy in 
patients with CD who have failed treatment with first-line and 
second-line drugs, or who are corticosteroid-dependent.
Induction of remission in fistulizing 
disease
IFX was approved for use in fistulizing CD based upon 
the results of two randomized controlled trials.15,16 One 
study included 94 patients who were unresponsive to at 
least 3 months of conventional therapy who were randomly 
assigned to receive three doses of IFX (5 or 10 mg/kg) 
or placebo at weeks 0, 2, and 6. After a follow-up of 26 
weeks, significantly more patients receiving IFX had 
a reduction in the number of draining fistulas without 
requiring an increase in other medications (68% and 56% 
in the 5 mg/kg or 10 mg/kg arm, respectively, vs 26% 
for placebo). Closure of all fistulas was observed in 55% 
and 38% of patients receiving the 5 mg/kg and 10 mg/kg 
dose, respectively, compared with 13% of those receiv-
ing placebo. This study did not address issues such as 
relapse rate after initial success or the potential benefit 
of combining IFX with immunomodulators or antibiot-
ics. Whether the combination of IFX and oral antibiotics 
improves efficacy is unclear and more evidence is needed. 
A randomized controlled trial involving 24 patients with 
severe perianal disease concluded that the combination of 
IFX plus ciprofloxacin (500 mg orally twice daily) was 
more effective than IFX alone.17 A prospective study18 
assessed the efficacy and safety of treatment of perianal 
CD by means of a combination of surgical management 
and a standardized protocol for the intravenous infusion of 
IFX showing that the combination of seton drainage and 
infusion of IFX completely healed the perineum in 47% 
of patients with complex fistulizing perianal CD. A small 
uncontrolled case series confirms these initial results.19 
Two open-label Italian studies20,21 evaluated IFX as a local 
injection adjacent to the perianal fistula tract in patients 
with CD and contraindications to systemic infusion, show-
ing encouraging results, but further controlled clinical 
investigations are warranted.
Maintenance of response  
and remission
Patients with moderate-to-severe luminal CD who have 
responded to an induction regimen with anti-TNF-α therapy 
should be considered for scheduled retreatment with or 
without concomitant immunomodulators. This strategy 
is more effective than episodic therapy for maintaining 
response. The largest and most comprehensive study of 
maintenance therapy (ACCENT I) was a multicenter, 
randomized, double-blind, international trial studying 
retreatment and maintenance of remission in patients with 
CD treated with IFX.22
The study included patients who had moderate-to-severe 
non-fistulizing CD (CDAI 220 to 400) for at least 3 months 
refractory to conventional treatment, and compared single-
dose with three-dose induction. Of the 573 patients entered 
into the study, 335 (58%) had a clinical response to IFX at 
2 weeks. Of the 473 responders, 325 (69%) responded by 
week 2 and another 127 (27%) by week 10. After 10 weeks, 
there was a statistically significant improvement in response 
and remission rates in the two groups that received scheduled 
maintenance therapy. Sixty-five percent of the patients had a 
clinical response (including 40% who achieved remission), 
while 31% demonstrated mucosal healing. In contrast, only 
28% of patients who received a single initial dose entered 
remission. The initial clinical response was maintained 
significantly more often in the two groups that received 
scheduled maintenance therapy (43% and 53% vs 17% in 
the 5 mg/kg, 10 mg/kg vs single-dose groups, respectively). 
After 54 weeks, the median duration of response was only 19 
weeks for patients in the single-dose group, compared with 
38 weeks for the IFX 5 mg/kg every 8 weeks group, and 
greater than 54 weeks for patients in the IFX 10 mg/kg 
every 8 weeks group. In patients who initially had a clinical 
remission, maintenance of remission occurred in only 14% 
of patients in the single-dose group compared with 28% of 
patients maintained on IFX 5 mg/kg every 8 weeks and 38% 
of patients on IFX 10 mg/kg every 8 weeks. Patients receiving 
scheduled therapy had significantly fewer CD-related hos-
pitalizations (23% vs 38%) and   surgeries (3% vs 7%). After 
54 weeks, clinical remission and successful tapering of the 
patient off steroids was observed significantly more often in 
the two scheduled maintenance groups (28% and 32% vs 9% 
in the 5 mg/kg and 10 mg/kg groups vs the single infusion 
group, respectively). Of particular importance, significantly 
more patients receiving scheduled IFX had discontinued 
glucocorticoids and were also in clinical remission with a 
CDAI , 150 (31% and 36.8% vs 10.7% for the 5 mg/kg and 
10 mg/kg doses vs placebo, respectively). Patients assigned to 
the scheduled maintenance groups had significant improve-
ment in quality-of-life as measured by a validated instrument 
(IBDQ).23 Furthermore, patients who could be maintained in Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
231
Infliximab for Crohn’s disease
remission had increased employment and fewer hospitaliza-
tions and surgeries.24 A recent meta-analysis25 confirms that 
IFX prevents relapse of quiescent luminal CD once remis-
sion has been achieved, maintains clinical remission (relative 
risk [RR]: 2.50; 95% confidence intervals [CI]: 1.64–3.80), 
maintains clinical response (RR: 1.66; 95% CI: 1.00–2.76), 
and has corticosteroid-sparing effects (RR: 3.13; 95% CI: 
1.25–7.81). Schnitzler et al26 assessed the long-term efficacy 
of IFX in a large cohort of patients who had CD, with a 
median follow-up of almost 5 years. The analysis demon-
strated excellent efficacy of IFX in maintaining improvement 
not only during 1 year as in the published trials but also 
during a median follow-up of 4.6 years, showing sustained 
clinical benefit defined as a lasting control of disease activity 
during follow-up, with persistent improvement of symptoms 
in 63.4% of patients.
Patients with fistulizing disease
Patients with fistulizing CD who have responded to an 
induction regimen with anti-TNF-α therapy should receive 
scheduled retreatment with IFX. The pivotal maintenance trial 
for IFX in fistulizing CD was ACCENT II which included 
306 adults with one or more draining abdominal or perianal 
fistulas of at least 3 months’ duration. Systematic treatment 
with IFX 5 mg/kg every 8 weeks was superior to placebo in 
both improvement and closure of draining fistulas over 54 
weeks. The median time to loss of response was .40 weeks 
vs 14 weeks on scheduled treatment with 5 mg/kg every 8 
weeks following three-dose induction therapy (see Figure 2 
which shows that IFX was more effective than placebo for 
complete fistula closure). Lichtenstein et al27 examined the 
effect of IFX maintenance treatment on hospitalizations, sur-
geries, and procedures in patients with fistulizing CD enrolled 
in the ACCENT II study and showed that among patients 
randomized as responders there was a .50% reduction in 
the mean number of CD-related hospitalizations compared 
with placebo maintenance treatment, and the length of stay of 
patients was also significantly reduced (from 2.5 to 0.5 days). 
IFX maintenance treatment was also associated with a .70% 
reduction in the mean number of CD-related inpatient surger-
ies and procedures, as well as major surgeries. Patients had an 
approximately 50% reduction in all surgeries and procedures, 
Risk difference
Total (Heterogeneity, P = 0.78) 16% (8–25%, 
         P < 0.001) 
Sands 2004 (ACCENT II) IFX
Schreiber 2007 (Precise 2) CERTO
Colombel 2007 (CHARM) ADA
Difference in effect:  treatment minus placebo (CI: 95%)
15% (3–27%)
10% (−15–36%)
20% (6–35%)
Weight (%)
37
12
52
100
0.0 −0.1 −0.2 0.1 0.2 0.3 0.4 0.5
Anti-TNF-α Controls
Figure 2 Infliximab was more effective than placebo for complete fistula closure.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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as compared with placebo maintenance treatment. An Italian 
multicenter group28 reported an initial response to induction 
with IFX in 76% of 188 patients with perianal CD and a 
44% clinical remission rate. The ACCENT I and ACCENT II 
studies have shown that scheduled maintenance therapy with 
IFX is superior to episodic therapy to maintain response and 
remission, both in luminal and in fistulizing CD.
Use of immunosuppressive agents 
in combination with IFX
There are conflicting opinions regarding the use of immu-
nosuppressive agents in combination with IFX due to 
several safety reports. The GETAID group evaluated the 
usefulness of short-term IFX combined with azathioprine 
or 6-mercaptopurine in 113 steroid-dependent CD patients 
stratified as follows: the failure stratum consisted of patients 
receiving azathioprine/6-mercaptopurine at a stable dose 
for more than 6 months, and the naïve stratum consisted 
of patients not treated previously with azathioprine/6-mer-
captopurine. Patients were randomized to IFX 5 mg/kg or 
placebo at weeks 0, 2, and 6. All patients were treated with 
azathioprine/6-mercaptopurine maintained at a stable dose 
throughout the 52 weeks of the study. The study demonstrated 
the benefits of initiating IFX treatment earlier by showing 
that IFX plus azathioprine combination therapy is more 
effective than azathioprine monotherapy in azathioprine-
naïve patients29 for achievement of remission (CDAI , 150) 
in the IFX group than in the placebo group (57% vs 29%, 
respectively) without steroids at week 24, and to reduce 
exposure to steroids. It is less clear whether it is beneficial 
to use the IFX-azathioprine combination in patients who 
previously failed therapy with azathioprine. The occurrence 
of hepatosplenic T cell lymphomas in patients on IFX in 
combination with azathioprine or 6-mercaptopurine, along 
with an increased incidence of opportunistic infections in 
patients on more than one immunosuppressive agent, led 
to the recommendation that IFX be given as monotherapy 
without concomitant immunosuppressive agents, mainly 
in a particular setting of patients. Data from the SONIC30 
study demonstrated that patients with moderate to severe CD 
treated with azathioprine 2.5 mg/kg/day in combination with 
IFX 5 mg/kg at weeks 0, 2, and 6 and then every 8 weeks, 
or IFX alone, are more likely to have a glucocorticoid-free 
clinical remission than those on azathioprine alone (57% 
and 44% vs 31%, respectively). The benefit was relevant 
in those with endoscopic or biochemical evidence of active 
inflammation. In contrast, there seems to be no synergism 
between methotrexate and IFX for the induction and main-
tenance of steroid-free remission in luminal CD.31 The 
Combination of Maintenance Methotrexate-IFX Trial was a 
randomized placebo-controlled study comparing methotrex-
ate in combination with IFX against IFX alone in patients 
who received prednisone induction therapy for active CD. 
The primary endpoint was time-to-treatment failure (success 
was CDAI , 150 through week 50 and no steroids). There 
were no differences in steroid-free remission between the two 
groups (76% and 77% at week 14; 56% and 57% at week 50). 
Because of the risks of combination therapy noted earlier, 
consideration can be given to using combination therapy and 
then having an “exit strategy”. This concept was addressed 
in a study of patients whose disease had been controlled 
for at least 6 months on maintenance IFX combined with 
immunosuppressive agents who were randomly assigned 
to continue or stop the immunosuppressive agents while 
they continued IFX maintenance therapy for up to 2 years;32 
the primary endpoint was the proportion of patients who 
required a decrease in the IFX dosing interval or stopped IFX 
therapy. The results of the study were that discontinuation of 
immunosuppressive agents after 6 months did not adversely 
affect either response or remission after IFX at the end of 2 
years. In contrast with these results, a recent paper postulated 
the usefulness of cotreatment with immunomodulators and 
scheduled IFX treatment.33 In patients with CD who have 
responded to 1 year of anti-TNF-α therapy, the benefits of 
continuing therapy should be weighed against the risks of 
discontinuation. Unfortunately, there are still insufficient 
data to make recommendations on when to stop anti-TNF-α 
therapy. Preliminary evidence suggests that for patients in 
clinical remission for more than 1 year, with a normal C-re-
active protein and mucosal healing, an appreciable propor-
tion will remain in remission during the year after stopping 
treatment. In a cohort study from Leuven, 20% of patients 
who had responded to IFX were able to stop therapy over a 
variable amount of time.34 A study of IFX discontinuation in 
CD patients in stable remission on combined therapy with 
immunosuppressor therapy recruited 115 patients in steroid-
free remission on IFX + azathioprine for more than 1 year 
and discontinued IFX. The relapse rate was 57% in the first 
year. Predictors of relapse included smoking, previous ste-
roid use, elevated fecal calprotectin, and elevated C-reactive 
protein. Randomized controlled data are required to confirm 
these observations. A significant portion of patients are 
termed “primary nonresponders” and do not show improve-
ments in their symptoms at the end of induction. Indeed, Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
233
Infliximab for Crohn’s disease
a significant rate of patients who initially respond to the 
treatment subsequently lose this response (termed “secondary 
failures”) and experience flares of disease necessitating dose 
escalation, switch to another anti-TNF-α drug, or surgical 
intervention. It has been shown that loss of response to anti-
TNF-α at 12 months of therapy occurs in 23%–46% of 
patients when judged by dose intensification, or 5%–13% 
when gauged by drug discontinuation rates.35   Several mecha-
nisms are proposed to explain loss of response to anti-TNF-α 
but the most investigated is immunogenicity due to antidrug 
antibodies. In a study focusing on these issues, anti-IFX 
antibodies were detected in 61% of 125 patients with refrac-
tory CD treated repeatedly during a 10-month period.36 The 
presence of antibody titers at a level of 8.0 µg/mL was signifi-
cantly associated with a shorter duration of response (35 days 
vs 71 days) and a higher risk of infusion reactions (relative 
risk 2.40). The concentration of IFX was significantly lower 
at 4 weeks among those patients who had an infusion reaction 
compared with those who never had an infusion reaction. 
The concomitant use of immunosuppressive therapy was 
predictive of low titers of anti-IFX antibodies and higher 
concentrations of IFX 4 weeks after infusion. It was shown 
that scheduled treatment is better than episodic because it 
elicits less immunogenicity and that loss of response can be 
prevented by concomitant immunomodulators.37
Extraintestinal manifestations
Maintenance therapy with IFX may be helpful in resolv-
ing extraintestinal manifestations of CD, particularly 
arthritis and arthralgias.38 In the case of failure of tradi-
tional therapy, the efficacy of anti-TNF-α agents is largely 
established,39 with an obvious advantage for patients with 
active intestinal disease. A large, prospective, open-label 
trial demonstrated improvement of peripheral arthritis 
in patients with IBD who had previously been refrac-
tory to corticosteroids, 6-mercaptopurine, azathioprine, 
or methotrexate. In this study, patients were treated with 
IFX 5 mg/kg at baseline (luminal CD) and at weeks 2 
and 6. At the end of 12 weeks, 36/59 (61%) patients had 
significant improvement of their arthritis, defined by 
improvement of one point in the arthritis component of 
CDAI score, and complete resolution of arthritis in 27/59 
(46%) patients.40 A small uncontrolled series supported 
the use of IFX in axial arthritis associated with IBD.41 
Cutaneous manifestations, such as   erythema nodosum 
and pyoderma gangrenosum, are   classically   associated 
with inflammatory bowel disease, occurring in 3%–20% 
and 0.5%–20% of patients,   respectively. In many cases, 
pyoderma gangrenosum refractory to standard medica-
tions (oral, intravenous, and intralesional corticosteroids, 
azathioprine, 6-mercaptopurine, antibiotics, dapsone, 
cyclosporine, FK506, and mycophenolate) has been suc-
cessfully treated with anti-TNF-α agents. In one small multi-
center, randomized, placebo-controlled trial (30 patients 
with pyoderma gangrenosum, 19 of whom also had IBD) 
IFX 5 mg/kg as a single infusion has been compared with 
placebo.42 A response was observed in 46% of patients 
receiving IFX compared with 6% of those receiving pla-
cebo (P = 0.0025). Ocular manifestations developed in 
2%–6% of patients with IBD, with the most common being 
episcleritis and uveitis. Many case reports and pilot stud-
ies have demonstrated that IFX can suppress uveitis and 
scleritis associated with various autoimmune disorders, 
including IBD.
Predictors of response in luminal 
and fistulizing CD
Smoking and concomitant use of immunosuppressive drugs 
appear to have an important influence on the initial response 
and durability of response in patients with inflammatory 
disease. A study from the Cleveland Clinic included 100 
patients with inflammatory or fistulous CD who were fol-
lowed for at least 3 months after treatment.43 In those with 
inflammatory disease, an initial response was significantly 
more likely in nonsmokers (73% vs 22%) and in those 
taking concurrent immunosuppressive medications (74% 
vs 39%). A prolonged response (more than 2 months) was 
also more likely in nonsmokers (59% vs 6%) and in those 
taking concomitant immunosuppressive medications (65% 
vs 18%). For those with fistulous disease, overall response 
rates were no different between smokers and nonsmokers, 
but nonsmokers had a longer duration of response. Patients 
with isolated colonic disease,44 those of young age,45 those 
with endoscopic evidence of ileocolonic ulcers at baseline, 
and those with an elevated C-reactive protein had a better 
response, whereas those with stricturing disease46 or previous 
abdominal disease47 were less likely to respond.48
Safety
Although short- and long-term anti-TNF-α therapy is 
generally well tolerated, clinicians must be vigilant for 
the occurrence of infrequent but serious adverse events 
(see Table 2). A long-term report of safety data over a 
14-year period reported a 13% rate of severe adverse events Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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vs 19% in placebo group. A recent review compared the rate 
of different adverse events among biologics and placebo, 
and concluded that serious adverse events such as infec-
tions, lymphoma, and congestive heart failure did not have 
a significantly different incidence between biologics and 
control treatment. IFX was associated with a significantly 
higher risk of withdrawals due to adverse events compared 
with controls (odds ratio: 2.04, 95% CI: 1.43–2.91; number 
needed to harm = 12, 95% CI: 8–28).49
 Safety data from the SONIC trial demonstrated that the 
rate of adverse events was similar among the IFX mono-
therapy, IFX plus azathioprine, and azathioprine mono-
therapy groups. Infusion reactions occurred less frequently 
among patients receiving combination therapy but the risk 
of opportunistic infections increases when TNF-α therapy is 
combined with additional immunosuppressive treatment.
A report from the Mayo Clinic described the clinical 
experience in 500 patients who received a median of three 
infusions and were followed up for a median of 17 months.50 
Although the authors concluded that therapy was generally 
well tolerated, they warned that clinicians using IFX should 
be vigilant for the occurrence of infrequent but serious 
adverse events, particularly in elderly patients. A more recent 
paper reports that patients older than 65 years treated with 
TNF inhibitors for IBD have a high rate of severe infections 
and mortality compared with younger patients or patients of 
the same age who did not receive these drugs.51
The most important concerns with prolonged use of 
biologics are related to cancer risk. A recent multicenter, 
matched-pair study assessed whether IFX use in CD for a 
median of 6 years is associated with an increased frequency 
of neoplasia in the long term. The authors concluded that the 
frequency of neoplasia was comparable in an adult popula-
tion of CD patients treated or not with IFX.52 Toxicity can 
be significantly reduced by routine tuberculosis screening, 
and by   avoiding anti-TNF agents in patients with heart 
failure, chronic   infections, or previous neoplastic disease. 
  Prospective, observational   studies with longer follow-up, such 
as the TREAT registry,53 will continue to provide more useful 
information on this issue, and clinicians need to remain aware 
of the potential for serious adverse events during longer-term 
exposure beyond the confines of clinical trials. Patients with 
intestinal strictures due to CD may be less likely to respond 
to treatment and are also at risk for developing acute bowel 
obstruction. These issues were examined in a review of data 
from the TREAT study and the ACCENT studies.54 In the 
TREAT study, intestinal stenosis, strictures, and obstruction 
occurred significantly more often in patients receiving IFX 
compared with those receiving other treatments. However, 
on multivariate analysis, the only independent predictors of 
stenosis were the severity and duration of CD, the presence 
of ileal disease and new glucocorticoid use. In ACCENT 
I, no increase in stenosis was described in those receiving 
IFX maintenance therapy compared with those who received 
episodic therapy. Thus, these data do not support a causal role 
for IFX in the development of stenosis.
Early treatment
In recent years the hypothesis that early treatment with 
biologics may influence the natural history of CD has devel-
oped.55 The early approach can be interpreted in terms of early 
onset in patients with newly diagnosed CD, or to prevent 
postoperative relapse. In patients with newly diagnosed CD 
naïve for corticosteroids, immunosuppressants, or biologics, 
the early use of combined immunosuppression (IFX plus 
azathioprine) is more effective than conventional manage-
ment for induction of remission and reduction of corticos-
teroid use. These data suggest that reversing the treatment 
paradigm from a “step-up” to a “top-down” approach may 
positively alter the natural course of this illness. The evidence 
indicates that early use of biologic therapy, in combination 
with immunomodulators, resulted in remission occurring 
more rapidly than the conventional “step-up” treatment, with 
a longer time period to relapse, decreased need for treatment 
with corticosteroids, faster reduction in clinical symptoms, 
rapid decline in biochemical inflammatory markers (C-re-
active protein), and improved endoscopic mucosal healing. 
In 2006, a retrospective study of 1123 patients identified 
clinical factors associated with a subsequent 5-year disabling 
course of CD56 suggesting that patients presenting at a young 
age with stricturing disease, needing initial treatment with 
  steroids, and with perianal disease at diagnosis have a poorer 
prognosis. Such patients may benefit from early introduction 
of biologic or immunomodulator therapy. However, the cor-
rect approach is debated.
Table 2 Adverse events associated with infliximab use
Infections (opportunistic and mycobacterial)
Cytokine release reactions
Autoimmunity (formation of antinuclear and DNA antibodies)
Malignancies
Heart failure
Demyelination
Liver function abnormalities
Dermatologic complications (psoriasis and other skin lesions)Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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The impact of IFX on recurrence in the postoperative 
setting had not yet been reported.
Sorrentino et al57 studied 12 consecutive patients treated 
immediately after surgery who maintained clinical and 
endoscopic remission with maintenance IFX 5 mg/kg for 
24 months after surgery, and whose IFX treatment was 
discontinued. At 4 months after discontinuation of IFX, 
10 of the 12 patients (83%) developed endoscopic recur-
rence (Rutgeerts score i2, i3, or i4). The 10 patients were 
treated again with IFX 3 mg/kg every 8 weeks, and mucosal 
integrity was then restored and maintained for 1 year. From 
their findings, long-term maintenance therapy with IFX 
is required to maintain mucosal integrity in patients after 
surgery for CD.
Subsequently, Regueiro et al58 conducted a randomized, 
double-blind, placebo-controlled trial in 24 patients with 
CD who had undergone ileocolonic resection and were 
allocated to receive intravenous IFX (5 mg/kg, n = 11) or 
placebo (n = 13) administered within 4 weeks of surgery 
and continued for 1 year. The endoscopic recurrence rate 
at 1 year was significantly lower in the IFX group (9.1%) 
compared with the placebo group (84.6%). The histologic 
recurrence rate at 1 year was significantly lower in the IFX 
group (27.3%) compared with the placebo group (84.6%). 
From these results, 1 year of IFX treatment after surgery was 
effective for preventing endoscopic and histologic recur-
rences of CD, but some clarifications should be made. The 
population included was at high risk for recurrence and this 
could explain the high rate of recurrence in the placebo group. 
It is notable that almost half of the study patients continued 
to receive immunomodulator therapy and this could raise a 
safety issue. Although it had a small sample size, this study 
provides the strongest evidence for the efficacy of postopera-
tive IFX therapy, but a larger prospective randomized trial 
to evaluate the sustained efficacy of IFX as a single agent to 
prevent postoperative recurrence is desirable.
IFX cannot be recommended for all patients after 
surgery because of potential adverse events and high 
medical costs. IFX should be used for patients at high risk 
of postoperative recurrence. Recently, Yamamoto et al59 
  conducted a prospective pilot study to investigate the 
efficacy of IFX in preventing early endoscopic recurrence 
after ileocolonic resection, and showed that IFX therapy 
reduced clinical and endoscopic disease activity in patients 
with early endoscopic recurrence after surgery. Clearly, the 
effectiveness of such a strategy should be demonstrated 
with longer follow-up.
Pregnancy
IFX is currently rated as a class B medication for preg-
nancy. Although large molecules like IFX do not cross 
the placenta during the early stages of pregnancy, it has 
recently been shown that there are detectable levels pres-
ent in fetal serum at birth,60 indicating that there may be 
diffusion across the placenta in the third trimester. These 
findings suggest that pregnant patients should avoid thera-
peutic antibody treatments after 30 weeks’ gestation, and 
if necessary, the expectant mother can be bridged with 
steroids to control disease activity until delivery. One 
report identified 131 pregnancies in which the women were 
exposed directly to IFX for treatment of CD or rheumatoid 
arthritis.61 Outcome data were available for 96 of these 
women. Rates of live births, miscarriages, and therapeutic 
terminations was similar to those expected for the general 
population of pregnant women or pregnant women with CD   
not exposed to IFX. In the TREAT registry, of the 5807 
patients enrolled, 66 pregnancies were reported, 36 of 
them with prior IFX exposure. Fetal malformations did 
not occur in any of the pregnancies. Rates of miscarriage 
and neonatal complications were not significantly differ-
ent between IFX-treated and IFX-naïve patients (11.1% 
vs 7.1% and 8.3% vs 7.1%, respectively). Despite these 
encouraging observations, prospective data will be needed 
to determine more definitively the risk of IFX therapy prior 
to conception and during pregnancy. There are no available 
data on the use of IFX during breast feeding, except some 
case reports suggesting placental rather than breast milk 
transfer of IFX.
Conclusion
IFX has become a powerful tool for the treatment of moder-
ately to severely active CD that is refractory to conventional 
therapy, improving quality of life in a significant proportion 
of patients suffering with CD. Clinical trials have demon-
strated significant   utility of IFX for induction of remission 
in moderately active, steroid-refractory CD and mainte-
nance of remission in these patients for up to 54 weeks after 
initial infusion. For fistulizing CD, the efficacy of IFX for 
inducing fistula closure is best documented. Patients receiv-
ing scheduled therapy had significantly fewer CD-related 
hospitalizations. Long-term follow-up has underscored the 
benefit of therapy in properly selected patients in order to 
avoid widespread use.
According to current European62 and Italian63 guidelines 
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Association guidelines64 on the use of biologics in IBD, 
biological therapy is indicated in steroid-refractory, 
steroid-dependent, and/or immunomodulator-refractory 
IBD, in patients intolerant to these conventional thera-
pies, and in conjunction with surgical drainage when 
CD is complicated by a complex fistula. Unfortunately, 
there are still insufficient data to make recommendations 
on when to stop anti-TNF therapy, and the benefits of 
continuing therapy should be weighed against the risks 
of discontinuation. A number of adverse events have 
been described following treatment with IFX, and thus 
providers and patients should be familiar with the risks as 
well as appropriate measures to prevent and monitor for 
complications.
Keypoints
•  IFX therapy in CD is effective at inducing and maintain-
ing remission in steroid-refractory, steroid-dependent, 
and/or immunomodulator-refractory IBD, and in patients 
intolerant to conventional therapies. 
•  IFX allows more profound control of bowel inflammation 
resulting in mucosal healing than conventional therapies, 
which could translate into improvement in long-term 
outcome of the disease course. 
•  Preliminary data show that IFX therapy decreases the 
need for hospitalizations and surgery in patients with 
luminal or fistulizing CD. 
•  Clinical data demonstrate an excellent efficacy and safety 
profile in selected patients. 
•  IFX works best in patients with evidence of active inflam-
mation as demonstrated by an elevated C-reactive protein 
and patients with nonstricturing disease. 
•  From the current evidence, an association with immuno-
modulators should be evaluated carefully.
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